Literature DB >> 22010387

FDA approves vemurafenib for treatment of metastatic melanoma.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22010387

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  5 in total

1.  A three-stage biophysical screening cascade for fragment-based drug discovery.

Authors:  Ellene H Mashalidis; Paweł Śledź; Steffen Lang; Chris Abell
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

2.  Melanoma patients under vemurafenib: prospective follow-up of melanocytic lesions by digital dermoscopy.

Authors:  Marie Perier-Muzet; Luc Thomas; Nicolas Poulalhon; Sébastien Debarbieux; Pierre-Paul Bringuier; Gerard Duru; Lauriane Depaepe; Brigitte Balme; Stephane Dalle
Journal:  J Invest Dermatol       Date:  2013-11-07       Impact factor: 8.551

Review 3.  What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment.

Authors:  Enrico Bronte; Giuseppe Bronte; Giuseppina Novo; Fabrizio Bronte; Maria Grazia Bavetta; Giuseppe Lo Re; Giuseppe Brancatelli; Viviana Bazan; Clara Natoli; Salvatore Novo; Antonio Russo
Journal:  Oncotarget       Date:  2015-11-03

Review 4.  Precision medicine in pediatric oncology.

Authors:  Suzanne J Forrest; Birgit Geoerger; Katherine A Janeway
Journal:  Curr Opin Pediatr       Date:  2018-02       Impact factor: 2.856

5.  Reliability of BRAF mutation detection using plasma sample: A systematic review and meta-analysis

Authors:  Peng Ye; Peiling Cai; Jing Xie; Jie Zhang
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.